VDRM (ViaDerma) Notes Receivable: $0.00 Mil (As of Jun. 2012)


What is ViaDerma Notes Receivable?

ViaDerma VDRM Notes Receivable is $0.00 Mil as of Jun. 2012.

ViaDerma's Notes Receivable for the quarter that ended in Jun. 2012 was $0.00 Mil.


ViaDerma Notes Receivable Historical Data

* Premium members only.

The historical data trend for ViaDerma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma Notes Receivable Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
Notes Receivable
0.00 0.00 0.00 0.00 0.00

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ViaDerma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
ViaDerma (VDRM) has a Notes Receivable of $0.00 Mil as of Jun. 2012. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ViaDerma and its competitors.
Is ViaDerma's Notes Receivable too high?
ViaDerma's current Notes Receivable is $0.00 Mil.
How does ViaDerma's Notes Receivable compare to AOLS and RDGL?
ViaDerma's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ViaDerma and its competitors. ViaDerma's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViaDerma stock overvalued right now?
ViaDerma (VDRM) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For ViaDerma (VDRM), the current Notes Receivable is $0.00 Mil as of Jun. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ViaDerma Business Description

Address 4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.